DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* NICOX *


 

1996 - Méditerranée
Nice
www.nicox.com

 

Delivery, Drugs
Key words: Nitric oxide, Inflammation, Cardio-metabolic, Osteo-arthritis
Mission: to develop and market investigational nitric oxide-donating drugs to meet unmet medical needs, based on proprietary nitric oxide-donating technology
Clients: Prescribers
nicox@nicox.com

Age: 21 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Garufi (Michele) [co-founder, born 1954, Pharm.D., ex-Recordati, Italfarmaco]
Sc.Dir.-CSO: Pfister (Pascal) [M.D., Pharm.D., ex-Novartis, Sandoz]
Fin.Dir.-CFO: Castaldi (Eric)
BusDev: Spencer (Gavin) [Ph.D. chemistry, ex-Novartis, Boots]
Financers (Hist.): Apax Partners, Sofinnova, European Medical Ventures, Paribas P.I., Health Capital AB, Oppenheimer Funds, QVT Fund, AQR Capital Management, Pfizer Overseas, Baker Brothers Investments, Public, Managers (less than 3% in 2008)

Turnover (M€) : 0.16 (2011), 0.34 (2010), 2.9 (2008), 3.2 (2007)
Total funding (M€) : 380
Last funding (M€) : 100
Focus : Multiple
Position : Pre-reg
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .10 Launch of AdenoPlus in USA (new device for differential diagnosis of acute conjunctivitis) MKTG [16 years]
2012 .04 Acquisition of 11.8 % stake in UK Altacor (to build an international ophthalmology business) for 2.0 M€, with option to acquire the entire company (declined in June) ACQ+ [16 years]
2012 .03 Clinical trial (phase IIb) for BOL-303259-X (end, positive), a novel nitric oxide-donating prostaglandin F2-alpha analog, in patients with open-angle glaucoma (with Bausch & Lomb) CLIN [16 years]
2011 .12 Management restructuring : 33% heads employee reduction (after 50 heads dropped earlier in 2010) ORGR [15 years]
2011 .09 Development : preclinical data for NCX 6560, a nitric oxide (NO)-donating atorvastatin R&D [15 years]
2011 .03 Partnering distribution agreement with Ferrer (Spain) on co-marketing rights of naproxcinod in Spain and Germany, and on exclusive marketing rights in Greece and Portugal MKTG [15 years]
2010 .08 Closure of US subsidiary (headquarters) in New Jersey ORGC [14 years]
2010 .05 Registration : FDA advisory panel rejects naproxcinod (stock market off 45%, after announcement) MKTG [14 years]
2009 .12 Public offering : 100 M€, with capital increase (closed) to FSI (€ 20 Millions), public funds (€ 10 Millions) and existing shareholders (€ 70 Millions) PBO [13 years]
2009 .09 Registration : FDA submission of naproxcinod (then, EMEA, in December) MKTG [13 years]
2009 .08 Acquisition (re-acquisition) of rights to PF-03187207 for glaucoma from Pfizer for 2 undisclosed milestones ACQ+ [13 years]
2009 .04 Acquisition of Nitromed's unlicensed patent estate covering nitric oxide-donating compounds for up to 6.0 M€ ACQ+ [13 years]
2008 .09 Partnering secondary production agreement with Capsugel for the manufacture of Naproxcinod INDUS [12 years]
2008 .05 Partnering primary production agreement with Archimica for the manufacture of Naproxcinod INDUS [12 years]
2007 .10 Set-up of US subsidiary (headquarters) in New Jersey ORGC [11 years]
2007 .07 Round-financing : 5.0 M€, by M.S.D., as milestone payment for licensing-in drug for hypertension RFIN [11 years]
2007 .02 Public offering : 130 M€, with capital increase PBO [11 years]
2006 .05 Clinical trial (phase III) for HCT3012 osteoarthritis drug (end of patient recrutment) CLIN [10 years]
2006 .04 3rd round-financing : 45.5 M€, for private international investors, with share increase and subsequent listing on Euronext RFINC [10 years]
2004 .10 2nd round-financing : 26.0 M€, for private international investors, with share increase and subsequent listing on Euronext RFINB [8 years]
2003 .02 Financing : stock drop-down from 210 M€ to 36 M€ (max.: 450 M€ in June 2002), after disappointing results of clinical study INFO [7 years]
2004 .08 Partnering research agreement with Pfizer R&D [8 years]
2001 .09 Set-up of R&D center in northern Italy ORGC [5 years]
2001 .05 Public offering : 59.0 M€ PBO [5 years]
1999 .11 Listing on Paris Nouveau Marché : 27.4 M€ PBO [3 years]
1998 .06 Company move from Paris to Sophia Antipolis (near Nice) ORGL [2 years]
1998 .03 Partnering research agreement with Bayer (first of long series) R&D [2 years]
1997 .12 1st round-financing : 6.4 M€, led by Paribas P.I., Health Capital AB, with previous investors RFINA [1 year]
1996 .10 Clinical trial (phase I) for anti-thrombotic (beginning) CLIN [0 year]
1996 .02 Company founded by 3 pharmaceutical executives, Michele Garufi (CEO), Piero del Soldato, Elizabeth Robinson, from a primary legal entity in Eire in 1994, with financial support of Apax Partners, Sofinnova, European Medical Ventures ORGF [0 year]

Actualisation / Updating: 21-Nov-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende